MET receptor sequence variants R970C and T992I lack transforming capacity

Jeffrey W. Tyner, Luke B. Fletcher, Ellen Q. Wang, Wayne F. Yang, Michael L. Rutenberg-Schoenberg, Carol Beadling, Motomi (Tomi) Mori, Michael C. Heinrich, Michael W. Deininger, Brian J. Druker, Marc M. Loriaux

Research output: Contribution to journalArticlepeer-review

61 Scopus citations


High-throughput sequencing promises to accelerate the discovery of sequence variants, but distinguishing oncogenic mutations from irrelevant "passenger" mutations remains a major challenge. Here we present an analysis of two sequence variants of the MET receptor (hepatocyte growth factor receptor) R970C and T992I (also designated R988C and T1010I). Previous reports indicated that these sequence variants are transforming and contribute to oncogenesis. We screened patients with chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), colorectal cancer, endometrial cancer, thyroid cancer, or melanoma, as well as individuals without cancer, and found these variants at low frequencies in most cohorts, including normal individuals. No evidence of increased phosphorylation or transformative capacity by either sequence variant was found. Because small-molecule inhibitors for MET are currently in development, it will be important to distinguish between oncogenic sequence variants and rare singlenucleotide polymorphisms to avoid the use of unnecessary, and potentially toxic, cancer therapy agents.

Original languageEnglish (US)
Pages (from-to)6233-6237
Number of pages5
JournalCancer Research
Issue number15
StatePublished - Aug 1 2010

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'MET receptor sequence variants R970C and T992I lack transforming capacity'. Together they form a unique fingerprint.

Cite this